AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Clinical trial NCT05209152 · TERMINATED

Trial details

NCT number: NCT05209152
Sponsor: Amgen
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Higher Risk Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia

Start date: 2022-11-14
Primary completion: 2023-12-19
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.